

(5,448/49.5%), Latin America (1,805/16.4%), MidEast/Africa (861/7.8%), and North America (1,145/10.4%).

Results. Ceftazoline and comparator agent activities are summarized in the following table.

Table

Organism (n)*	MIC ₉₀ (µg/mL)/%Susceptible				
	CPT	CRO	LZD	DAP	ERY
<i>Staphylococcus aureus</i> , MRSA (2,454)	1/91.4	>64/na	2/100	1/99.8	>8/33.8
<i>Staphylococcus aureus</i> , MSSA (2,692)	0.25/99.9	4/na	2/100	0.5/100	8/77.3
<i>Staphylococcus epidermidis</i> (1,978)	0.5/98.0	>32/na	2/98.7	1/99.9	>8/30.1
<i>Streptococcus pneumoniae</i> (2,421)	0.12/99.9	0.5/97.4	1/100	0.5/0	8/76.0
Beta-hemolytic streptococci (1,453) [†]	0.015/100	0.12/99.9	1/100	0.5/100	>1/80.5

* n refers to number of isolates tested against ceftazoline; numbers may vary for comparators (range 1031-5785); [†] includes *S. agalactiae* (n=342), *S. dysgalactiae* (n=305), and *S. pyogenes* (n=806).
CPT, ceftazoline; CRO, ceftriaxone; LZD, linezolid; DAP, daptomycin; ERY, erythromycin; na, no MIC breakpoints available.

Conclusion. Greater than 98% of *S. pneumoniae*, *S. epidermidis*, beta-hemolytic streptococci and MSSA isolates included in a 2012-2018 collection of gram-positive blood stream pathogens were susceptible to ceftazoline. 91.4% of MRSA were susceptible, and 8.6% isolates categorized as susceptible-dose dependent (MIC, 2-4 µg/mL); two isolates (one each from Thailand and S. Korea) were resistant to ceftazoline (MIC >4 µg/mL). Ceftazoline continues to demonstrate potent *in vitro* activity against clinically relevant pathogens associated with BSI.

Disclosures. Greg Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahn, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacteriales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018

Krystyna Kazmierczak, PhD¹; Francis Arhin, PhD²; Greg Stone, PhD³; Daniel F. Sahn, PhD¹; IHMA, Inc., Schaumburg, IL; ²Pfizer Canada, Kirkland, Quebec, Canada; ³Pfizer, Inc., Groton, Connecticut

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Avibactam (AVI) is a serine-β-lactamase inhibitor in development with aztreonam (ATM) for treatment of infections caused by drug-resistant Enterobacteriales (Ent), especially carbapenem-resistant isolates co-producing serine- and metallo-β-lactamases (MBL), which are often resistant to agents from multiple drug classes. This study evaluated the *in vitro* activity of ATM-AVI and comparators against Ent collected globally as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program.

Methods. 44,671 non-duplicate clinical isolates were collected in 2016-2018 in 52 countries in Europe, Asia/Pacific (excluding China and India), Middle East/Africa, and Latin America. Susceptibility testing was performed by CLSI broth microdilution and interpreted using CLSI 2020 and FDA (tigecycline) breakpoints. ATM-AVI was tested at a fixed concentration of 4 µg/mL AVI. Drug-resistant phenotypes were defined as: multidrug resistant (MDR), resistant (R) to ≥3 of 7 sentinel agents (amikacin [AMK], ATM, cefepime [FEP], colistin [CST], levofloxacin [LVX], meropenem [MEM], piperacillin-tazobactam [TZP]); extensively drug resistant (XDR), susceptible to ≤2 sentinel agents; and pandrug resistant (PDR), non-susceptible to all sentinel agents. Isolates with MEM MIC >1 µg/mL were screened for β-lactamase genes by PCR and sequencing.

Results. 14.9%, 4.3%, 3.7%, 1.3%, and 0.3% of Ent collected globally were MDR, XDR, MEM-R, MBL-positive, and PDR, respectively. ATM-AVI tested with MIC₉₀ values of 0.12 µg/mL against all Ent and 0.5 µg/mL against subsets of resistant isolates (Table). On the regional level, similar values were observed against all (MIC₉₀, 0.12 µg/mL) and resistant isolates (MIC₉₀, 0.25-1 µg/mL) (not shown). The tested comparators, excluding TGC, showed percentages of susceptibility < 90% against regional and global subsets of resistant isolates. 99.97% (44658 of 44671) Ent, including all MBL-positive and PDR isolates, were inhibited by ≤8 µg/mL of ATM-AVI.

Table

Phenotype (n)	Drug (MIC ₉₀ [µg/mL]/ % Susceptible)									
	ATM-AVI		ATM		MEM		TGC			
	MIC ₉₀	% S	MIC ₉₀	% S	MIC ₉₀	% S	MIC ₉₀	% S		
All Enterobacteriales (44671)	0.12	NA	64	74.2	0.12	95.7	8	97.4	1	97.0
MEM-R (1645)	0.5	NA	>128	10.7	>8	0.0	>32	64.1	2	91.9
MDR (6662)	0.5	NA	>128	4.8	>8	73.0	>32	84.4	2	94.2
XDR (1936)	0.5	NA	>128	4.0	>8	16.8	>32	55.7	2	91.0
PDR (151)	0.5	NA	>128	0.0	>8	0.0	>32	0.0	4	75.5
MBL+ (582)	0.5	NA	>128	19.6	>8	5.2	>32	59.1	4	87.1

ATM-AVI, aztreonam-avibactam; ATM, aztreonam; MEM, meropenem; AMK, amikacin; TGC, tigecycline; R, resistant; MDR, multidrug resistant (R to ≥3 of 7 sentinel agents [ATM, MEM, AMK, cefepime, colistin, levofloxacin, piperacillin-tazobactam]); XDR, extensively drug resistant (susceptible (S) to ≤2 sentinel agents); PDR, pandrug resistant (S to 0 sentinel agents); MBL+, metallo-β-lactamase-positive (a gene encoding an MBL was detected by PCR); NA, no breakpoints available. % Susceptible was determined using CLSI 2020 breakpoints for all agents except TGC. TGC MICs were interpreted using U.S. FDA breakpoints.

Conclusion. Based on MIC₉₀ values, ATM-AVI demonstrated potent *in vitro* activity against resistant and MBL-positive subsets of Ent collected globally. ATM-AVI could be an effective therapy for difficult-to-treat infections caused by drug-resistant Ent.

Disclosures. Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Francis Arhin, PhD, Pfizer, Inc. (Employee) Greg Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahn,

PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)

1568. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacteriales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Pediatric Patients, ATLAS Surveillance Program, 2015-2018

Krystyna Kazmierczak, PhD¹; Greg Stone, PhD²; Daniel F. Sahn, PhD¹; IHMA, Inc., Schaumburg, IL; ²Pfizer, Inc., Groton, Connecticut

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with *in vitro* activity against Enterobacteriales (Ent) and *Pseudomonas aeruginosa* (*Psa*) carrying Class A, C and some Class D β-lactamases. We examined the *in vitro* activity of CAZ-AVI and comparators against presumed community-acquired (CA; cultured < 48 h after hospital admission) and hospital-acquired (HA; cultured ≥48 h post-admission) isolates collected from pediatric patients as part of the ATLAS surveillance program.

Methods. 6023 non-duplicate isolates were collected in 50 countries in Europe (n=3122), Latin America (n=1220), Middle East/Africa (n=1007), and Asia/Pacific (excluding China; n=674) from patients (newborn to 17 y) with lower respiratory tract (LRTI; n=1641), urinary tract (UTI; n=1595), skin and soft tissue (SSTI; n=1027), intra-abdominal (IAI; n=949), and bloodstream (BSI; n=811) infections. Susceptibility testing was performed by CLSI broth microdilution and values were interpreted using CLSI 2020 breakpoints. CAZ-AVI was tested at a fixed concentration of 4 µg/mL AVI. Isolates with CAZ or aztreonam MICs ≥2 µg/mL (*Escherichia coli*, *Klebsiella* spp., *Proteus mirabilis*) or meropenem MICs ≥2 µg/mL (all Ent species) or ≥4 µg/mL (*Psa*) were screened for β-lactamase genes.

Results. The *in vitro* activity of CAZ-AVI exceeded that of meropenem and other tested β-lactams against Ent (98.5% susceptible (S)) and *Psa* (93.1% S) collected globally from pediatric patients (Table). Percentages of susceptibility to CAZ-AVI ranged from 96.8-99.3% among CA Ent from different infection types and were reduced 0.4-1.0% among HA isolates from SSTI, IAI and BSI. Susceptibility to CAZ-AVI was also similar (92.7-95.4% S) among CA *Psa* from different infection types and was reduced 0.1-4.4% among HA isolates. For both Ent and *Psa*, the lowest percentages of susceptibility to the tested β-lactams were observed among isolates from BSI, which included a higher proportion of isolates carrying extended-spectrum β-lactamases and/or carbapenemases than isolates from other infection types.

Table

Organism (n, % of total) Drug	All Sources	% Susceptible (Infection Source/Length of Hospitalization)									
		LRTI		UTI		SSTI		IAI		BSI	
		<48 h	≥48 h	<48 h	≥48 h	<48 h	≥48 h	<48 h	≥48 h	<48 h	≥48 h
Enterobacteriales	4692 (100)	331 (32.2)	688 (67.8)	838 (59.9)	561 (40.1)	324 (42.0)	447 (58.0)	447 (55.9)	353 (44.1)	216 (31.2)	477 (88.8)
CAZ-AVI	98.5	98.2	98.1	98.3	98.3	98.3	97.8	99.3	98.3	98.3	98.4
CAZ	75.3	76.7	71.9	79.5	71.8	84.6	77.4	87.0	77.3	67.6	58.9
MEM	97.0	96.4	97.9	98.2	97.1	96.9	96.2	98.9	97.7	94.4	93.9
TZP	85.2	82.2	82.7	87.8	83.4	92.0	82.8	94.2	86.0	82.4	79.2
P. aeruginosa	1331 (100)	230 (37.6)	382 (62.4)	86 (43.9)	110 (56.1)	108 (42.2)	148 (57.8)	95 (63.8)	54 (36.2)	41 (34.7)	77 (65.3)
CAZ-AVI	93.1	94.8	91.4	93.0	92.7	95.4	95.3	94.7	92.6	92.7	88.3
CAZ	82.0	81.3	79.6	87.2	83.6	80.6	84.5	89.5	83.3	82.9	75.3
MEM	78.1	77.8	72.8	91.9	79.1	79.6	81.1	90.5	79.6	70.7	67.5
TZP	78.3	78.7	74.9	82.6	76.4	78.7	79.1	86.3	85.2	78.0	75.3

LRTI, lower respiratory tract infection; UTI, urinary tract infection; SSTI, skin and soft tissue infection; IAI, intra-abdominal infection; BSI, bloodstream infection; CAZ-AVI, ceftazidime-avibactam; CAZ, ceftazidime; MEM, meropenem; TZP, piperacillin-tazobactam. Isolates for which data regarding infection source and length of hospitalization were not available were excluded from analysis.

Conclusion. CAZ-AVI could provide a valuable therapeutic option for treatment of CA and HA infections caused by Ent and *Psa* in pediatric patients.

Disclosures. Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Greg Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahn, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Shionogi & Co., Ltd. (Independent Contractor)

1569. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacteriales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2015-2018

Krystyna Kazmierczak, PhD¹; Sibylle Lob, PhD¹; Greg Stone, PhD²; Daniel F. Sahn, PhD¹; IHMA, Inc., Schaumburg, IL; ²Pfizer, Inc., Groton, Connecticut

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Avibactam (AVI) is a β-lactamase inhibitor with potent inhibitory activity against Class A, Class C, and some Class D serine β-lactamases. The combination of ceftazidime (CAZ) with AVI has been approved in Europe and in the United States for several indications. This study evaluated the *in vitro* activity of CAZ-AVI and comparators against Enterobacteriales (*Eba*) and *Pseudomonas aeruginosa* (*Pae*) isolates collected from patients with bloodstream infections as part of the ATLAS surveillance program in 2015-2018.

Methods. A total of 57048 *Eba* and 15813 *Pae* non-duplicate clinically significant isolates, including 7720 *Eba* and 1286 *Pae* isolated from bloodstream infections, were collected in 52 countries in Europe, Latin America, Asia/Pacific (excluding mainland China), and the Middle East/Africa region. Susceptibility testing was performed by CLSI broth microdilution. CAZ-AVI was tested at a fixed concentration of 4 µg/ml AVI. Meropenem-nonsusceptible (MEM-NS) *Eba* and *Pae* isolates were screened for the presence of β-lactamase genes.